TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26634956

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BBUP) 150-450 µg every 12 hours
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BBUP)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 749
Study: 24985779

Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 1952

Group type: COMPARATOR
Intervention: Standard ART
Number of subjects: 1952
Study: 21931012

Group type: EXPERIMENTAL
Intervention: Endovenous laser treatment (EVLT)
Number of subjects: 400

Group type: COMPARATOR
Intervention: High ligation and stripping (HLS)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 400
Study: 20873270

Group type: EXPERIMENTAL
Intervention: Nutrition optimization as part of maintenance therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher motor activity
Number of subjects: 0
Study: 18390020

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN+)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No Patient Navigation (PN-)
Number of subjects: 21
Study: 16815467

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.25 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa (100/25 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 12707152

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 2074

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 2074
Study: 11056999

Group type: EXPERIMENTAL
Intervention: Two levels of stimulus-response compatibility
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Two levels of stimulus discriminability
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Two levels of response repertoire
Number of subjects: 104
Study: 8882175

Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bed nets (PIBs)
Number of subjects: 1398

Group type: COMPARATOR
Intervention: Control group (no bed nets)
Number of subjects: 1398
Study: 1448534

Group type: EXPERIMENTAL
Intervention: Silicone gel sheets (Spenco) worn continuously for 12 hours for 12 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Kenalog injection (40 mg/ml x 1 cc mixed with 1 cc of 1% Xylocaine with epinephrine)
Number of subjects: 14
Study: 2864962

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (30 g/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30809083

Group type: EXPERIMENTAL
Intervention: High nutrient drink (500 kcal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low nutrient drink (250 kcal)
Number of subjects: 20
Study: 29056072

Group type: EXPERIMENTAL
Intervention: 12-item ShortMAC
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Traditional 24-item WOMAC
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Pain subscale of ShortMAC
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Function subscale of ShortMAC
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Pain subscale of Traditional WOMAC
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Function subscale of Traditional WOMAC
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual medical care (Control)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Physical therapy (Intervention)
Number of subjects: 206
Study: 27809796

Group type: EXPERIMENTAL
Intervention: 8-week web-based stress management intervention (STREAM) with weekly written feedback by a psychologist
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 120
Study: 25350546

Group type: EXPERIMENTAL
Intervention: Simple text message reminders
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Additional message with adherence statement
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 1140
Study: 22199194

Group type: EXPERIMENTAL
Intervention: Auditory frequency discrimination task (AFD group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Auditory phonetic discrimination task (PD group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Visual frequency discrimination task (VFD group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: No-intervention control (NI group)
Number of subjects: 86
Study: 20136803

Group type: EXPERIMENTAL
Intervention: Vacuum interferential current (IFC) therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 18853934

Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release 12.5 mg
Number of subjects: 752
Study: 16815535

Group type: EXPERIMENTAL
Intervention: Reported smokers
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Cotinine-derived smokers
Number of subjects: 328
Study: 12826548

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 0.375%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postoperative local anesthetics and supplemental analgesics
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dynamic pain scores
Number of subjects: 30

Group type: COMPARATOR
Intervention: Side effects
Number of subjects: 30
Study: 10893016

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 microg once daily
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 microg once daily
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 microg twice daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All budesonide groups
Number of subjects: 57
Study: 8835835

Group type: EXPERIMENTAL
Intervention: VSF-ECG method (Voltage Sum of Filtered ECG)
Number of subjects: 0
Study: 1442757

Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 40 mg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3910296

Group type: EXPERIMENTAL
Intervention: Combination of 280 mg mefloquine, 800 mg sulfadoxine and 40 mg pyrimethamine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination of 420 mg mefloquine, 1200 mg sulfadoxine and 60 mg pyrimethamine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Combination of 1500 mg sulfadoxine and 75 mg pyrimethamine
Number of subjects: 75
Study: 30626217

Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (IHT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 30886093

Group type: EXPERIMENTAL
Intervention: Seniors in the United States
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seniors in elite institutions in the United States
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 0
Study: 28492197

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC) restorations
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Composite resin (CR) restorations
Number of subjects: 86
Study: 26478951

Group type: EXPERIMENTAL
Intervention: Busy Bodies/Better Bites Obesity Prevention Arm
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy Tots/Safe Spots safety/injury prevention Contact Control Arm
Number of subjects: 60
Study: 23493965

Group type: EXPERIMENTAL
Intervention: Talbinah consumption
Number of subjects: 30
Study: 20853262

Group type: EXPERIMENTAL
Intervention: Ocular Response Analyzer (ORA)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Corneal hysteresis (CH)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Corneal resistance factor (CRF)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Topical medications
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues
Number of subjects: 154
Study: 18076041

Group type: EXPERIMENTAL
Intervention: Highest quintile of triglycerides (>/=160 mg/dl)
Number of subjects: 2299

Group type: EXPERIMENTAL
Intervention: Lowest quintile of HDL (<30 mg/dl)
Number of subjects: 2299

Group type: EXPERIMENTAL
Intervention: Total cholesterol, LDL, and apo A
Number of subjects: 2299

Group type: EXPERIMENTAL
Intervention: Low and high levels of total cholesterol, LDL, apo A, and apo B
Number of subjects: 2299
Study: 16549410

Group type: EXPERIMENTAL
Intervention: Epley's manoeuvre
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 66
Study: 15309442

Group type: EXPERIMENTAL
Intervention: Rye bran breads (10.2 mg ferulic acid per day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control breads (inert wheat bran)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rye bran intervention
Number of subjects: 18
Study: 11057849

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 6595
Study: 9223886

Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution with Dextran 40 (Group II)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Albumin and lactated Ringer solution (Group III)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Without hemodilution (Group I)
Number of subjects: 156
Study: 8267190

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (300 micrograms)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (700 micrograms)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Open-label continuous epidural infusion of clonidine (10-50 micrograms/h)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 4005106

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31097085

Group type: EXPERIMENTAL
Intervention: First-line afatinib
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 553
Study: 28951026

Group type: EXPERIMENTAL
Intervention: Coping partnership intervention (1 home visit, weekly telephone calls for month 1, biweekly calls for months 2 and 3)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study: 27390074

Group type: EXPERIMENTAL
Intervention: Water dispensers with promotional activities and cups
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Bottleless water coolers with promotional activities and cups
Number of subjects: 595

Group type: COMPARATOR
Intervention: Traditional drinking fountains with no cups or promotion
Number of subjects: 595
Study: 25322696

Group type: EXPERIMENTAL
Intervention: Digital photographs of plain film CXRs
Number of subjects: 150

Group type: COMPARATOR
Intervention: Plain film CXRs viewed on a light box
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall comparison of both modalities
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for lung carcinoma and pneumonia images
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for pneumothorax, tuberculosis, interstitial disease, and normal images
Number of subjects: 150
Study: 22884414

Group type: EXPERIMENTAL
Intervention: Spironolactone (200mg, orally at 23:00 h and again at 4:00 h)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 11
Study: 19655179

Group type: EXPERIMENTAL
Intervention: DIAGNOdent (LF)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: DIAGNOdent (LFpen)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Sealants (two clear and two opaque)
Number of subjects: 166
Study: 17074300

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT) in RCT (N=30)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Cognitive-behaviour therapy (CBT) in routine practice (N=384)
Number of subjects: 414
Study: 16236225

Group type: EXPERIMENTAL
Intervention: Tailored internet-delivered newsletters
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard internet-delivered newsletters
Number of subjects: 31
Study: 12099542

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% three times daily for 12 weeks
Number of subjects: 215

Group type: COMPARATOR
Intervention: Acetazolamide 250-mg q.i.d. for 12 weeks
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 215

Group type: COMPARATOR
Intervention: Acetazolamide
Number of subjects: 215
Study: 10847958

Group type: EXPERIMENTAL
Intervention: 1 L of gas flow through the perfusate before bypass, starting FIO2 of 0.80
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: No gas flow through the perfusate prior to bypass, starting FIO2 of 0.21
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 1 L of gas flowing through the perfusate, starting FIO2 of 0.21
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High FIO2 settings
Number of subjects: 39
Study: 8678268

Group type: EXPERIMENTAL
Intervention: glucose solution + lipid emulsion
Number of subjects: 20

Group type: COMPARATOR
Intervention: fructose solution + lipid emulsion
Number of subjects: 20
Study: 1964153

Group type: COMPARATOR
Intervention: Standard chemotherapy (1000 mg/m2 cyclophosphamide, 50 mg/m2 doxorubicin, 1.4 mg/m2 vincristine)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy using three different drug-combinations (A: 1500 mg/m2 cyclophosphamide, 100 mg/m2 lomustine, 15 mg/m2 methotrexate; B: 1000 mg/m2 cyclophosphamide, 40 mg/m2 doxorubicin, 1 mg/m2 vincristine; C: 5 x 1.6 g/m2 ifosfamide plus mesna, 5 x 120 mg/m2 etopside)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Surgery followed by chemotherapy and radiotherapy
Number of subjects: 170
Study: 418984

Group type: EXPERIMENTAL
Intervention: Monistat Cream for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monistat Cream for 14 days
Number of subjects: 0
Study: 30520013

Group type: EXPERIMENTAL
Intervention: 12 infusions of rituximab (375 mg/m2) in combination with CHOEP chemotherapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: 6 infusions of rituximab (375 mg/m2) in combination with CHOEP chemotherapy (control group)
Number of subjects: 77
Study: 29490769

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride and fluticasone propionate (AZE/FP)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 404
Study: 27003488

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study: 23867044

Group type: EXPERIMENTAL
Intervention: Carotid stenting (n = 81)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) (n = 58)
Number of subjects: 139
Study: 22209640

Group type: EXPERIMENTAL
Intervention: Stimulant medication (individualized dose of psychostimulants such as methylphenidate or dextroamphetamine/amphetamine combination)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 18
Study: 19875400

Group type: EXPERIMENTAL
Intervention: Hospital at home (HaH) care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Inpatient hospital care (IHC)
Number of subjects: 80
Study: 17177040

Group type: EXPERIMENTAL
Intervention: Educational DVD (n = 22)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo DVD (n = 27)
Number of subjects: 49
Study: 15314858

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin administration in doses exceeding routine ones
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Plasma cryoprecipitate
Number of subjects: 161
Study: 11889659

Group type: EXPERIMENTAL
Intervention: Tailored self-care treatment program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual TMD treatment
Number of subjects: 0
Study: 9797623

Group type: EXPERIMENTAL
Intervention: Morphine (n=62)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Non-morphine treatment (n=33)
Number of subjects: 87
Study: 8592594

Group type: EXPERIMENTAL
Intervention: CU (cuprammonium) dialyser
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CTA (cellulose triacetate) dialyser
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All membranes (CTA, CU, PS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CTA, CU, PS (all membranes)
Number of subjects: 8
Study: 2378776

Group type: EXPERIMENTAL
Intervention: Propofol (1.34 mg/kg of LTM for ED50, 2.56 mg/kg of LTM for ED95)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 56
Study: 334609

Group type: EXPERIMENTAL
Intervention: Butacote, 200 mg b.d. for four weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Naproxen, 250 mg b.d. for four weeks
Number of subjects: 48
Study: 31121476

Group type: EXPERIMENTAL
Intervention: Westmead Program
Number of subjects: 91

Group type: COMPARATOR
Intervention: Lidcombe Program
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (Lidcombe Program)
Number of subjects: 91
Study: 28082464

Group type: EXPERIMENTAL
Intervention: OFF-to-ON conversion (emergent)
Number of subjects: 4718

Group type: EXPERIMENTAL
Intervention: OFF-to-ON conversion (elective)
Number of subjects: 4718

Group type: COMPARATOR
Intervention: Non-converted off-pump patients
Number of subjects: 4718
Study: 25892679

Group type: EXPERIMENTAL
Intervention: Very early mobilisation
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2104
Study: 23894322

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (individual lifestyle counselling, family session, cooking classes, supervised physical activity programme)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Control group (generic lifestyle advice)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 536

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 536
Study: 20717066

Group type: EXPERIMENTAL
Intervention: External pancreatic duct stent (n=23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No external pancreatic duct stent (n=22)
Number of subjects: 45
Study: 19185773

Group type: EXPERIMENTAL
Intervention: GoChi (120 mL/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16888542

Group type: COMPARATOR
Intervention: Classic microlumbar discectomy (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Preservation of the ligamentum flavum during microlumbar discectomy (Group B)
Number of subjects: 20
Study: 14740178

Group type: EXPERIMENTAL
Intervention: Regression-Estimated Input Function (REIF) method
Number of subjects: 44

Group type: COMPARATOR
Intervention: Real input functions
Number of subjects: 44
Study: 12621592

Group type: EXPERIMENTAL
Intervention: Public sector primary care patients
Number of subjects: 115

Group type: COMPARATOR
Intervention: Middle-income clinics patients
Number of subjects: 115
Study: 10197889

Group type: EXPERIMENTAL
Intervention: Adjunctive megavitamin and dietary treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group receiving 25 mg vitamin C and allergenic substances
Number of subjects: 19
Study: 8527549

Group type: EXPERIMENTAL
Intervention: Rifabutin (600 mg/d) in combination with ethambutol, streptomycin, and clarithromycin (500 mg b.i.d.)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Rifabutin (600 mg/d) in combination with ethambutol, streptomycin, and azithromycin (600 mg/d)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Rifabutin (600 mg/d)
Number of subjects: 26
Study: 2273082

Group type: EXPERIMENTAL
Intervention: Methyldopa (250 mg tid) for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7378251

Group type: EXPERIMENTAL
Intervention: Combination therapy (Phyllocontin Continus tablets and salbutamol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Phyllocontin Continus tablets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 20
Study: 30677187

Group type: COMPARATOR
Intervention: Usual basal insulin dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reduced (75%) basal insulin dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall sensor performance
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sensor performance during hypoglycaemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sensor performance during euglycaemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sensor performance during hyperglycaemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall glucose levels during exercise
Number of subjects: 10
Study: 28515020

Group type: EXPERIMENTAL
Intervention: DHA supplementation (2-2.7g/d)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: EPA supplementation (1-2.7g/d)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Corn oil (0g of EPA+DHA)
Number of subjects: 154
Study: 25823535

Group type: EXPERIMENTAL
Intervention: CAIX score ≥ 200
Number of subjects: 813

Group type: COMPARATOR
Intervention: CAIX score ≤ 100
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: CAIX > 85%
Number of subjects: 813
Study: 23449126

Group type: EXPERIMENTAL
Intervention: Topical enzymatically generated hydrogen peroxide (using glucose oxidase and glucose)
Number of subjects: 0
Study: 21538146

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 135

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 135
Study: 19811710

Group type: EXPERIMENTAL
Intervention: Topical 2% diltiazem hydrochloride, applied perianally twice daily for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.2% glyceryl trinitrate (GTN), applied perianally twice daily for 8 weeks
Number of subjects: 80
Study: 17311574

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydrogel lenses
Number of subjects: 30
Study: 15079108

Group type: EXPERIMENTAL
Intervention: Hypertonic colloid solution (250 ml of 7.2% NaCl/6% Hydroxyethylstarch)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual Ringer solution (control group)
Number of subjects: 30
Study: 11679441

Group type: EXPERIMENTAL
Intervention: Infusion of nitroglycerin (GTN) at 1 microg.kg(‐1).min(‐1) for 4 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiological saline infusion
Number of subjects: 40
Study: 9018621

Group type: EXPERIMENTAL
Intervention: Tubulization (11 cases)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional microsurgical repair (7 cases)
Number of subjects: 18
Study: 7524141

Group type: EXPERIMENTAL
Intervention: alfuzosin 2.5 mg TID
Number of subjects: 205

Group type: COMPARATOR
Intervention: placebo TID
Number of subjects: 205
Study: 30113638

Group type: EXPERIMENTAL
Intervention: GH treatment 1 mg/m2/d (≈0.035 mg/kg/d)
Number of subjects: 0
Study: 27068672

Group type: EXPERIMENTAL
Intervention: New amino acid-based formula (NAAF)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Commercial amino acid-based formula (AAF)
Number of subjects: 46